Regulus, AstraZeneca Deal Rekindles Interest in RNA

Regulus Therapeutics Inc., of La Jolla, Calif., inked another two deals related to its microRNA technology. Its agreement with London-based AstraZeneca plc calls for a $28 million up-front cash and equity payment, plus milestones, for development of three microRNA targets.

To continue reading subscribe now to BioWorld Asia (formerly International)